Pavol Jozef Safarik University, Faculty of Medicine, Department of Pharmacology, Kosice, Slovak Republic.
University of Veterinary Medicine and Pharmacy, Department of Pharmacology and Toxicology, Kosice, Slovak Republic.
J Appl Biomed. 2023 Dec;21(4):218-227. doi: 10.32725/jab.2023.019. Epub 2023 Nov 28.
Spisulosine (1-deoxysphinganine) is a sphingoid amino alcohol isolated from the sea clams that showed potent antiproliferative activity against a broad spectrum of solid tumors but failed in clinical trials due to neurotoxicity. However, its structural similarity to other bioactive sphingoids, interesting mode of action, and appreciable potency against cancer cells make it a suitable lead for future anticancer drug development. The present study was conducted to elucidate mechanisms of the antiproliferative/cytotoxic effects of newly synthesized spisulosine analog homospisulosine (KP7). The evaluation was performed on cervical carcinoma cells, representing an in vitro model of one of the most common cancer types and a significant worldwide cause of women's cancer mortality. Treatment with homospisulosine (2.0 μM) for 24, 48, and 72 h significantly inhibited the growth of HeLa cells in vitro and induced apoptosis detectable by DNA fragmentation, externalization of phosphatidylserine, dissipation of mitochondrial membrane potential, activation of caspase-3 and cleavage of PARP. In addition, treating HeLa cells with spisulosine increased p27 and Bcl-2 on protein levels and phosphorylation of Bcl-2 on Ser70 residue. These results support the potential for spisulosine analogs represented here by homospisulosine for future therapeutic development.
螺旋甾辛胺(1-脱氧鞘氨醇)是从海蛤中分离出的一种神经酰胺样氨基醇,对多种实体瘤具有很强的抗增殖活性,但由于神经毒性,在临床试验中失败。然而,它与其他生物活性神经酰胺的结构相似、有趣的作用模式以及对癌细胞的相当大的活性,使其成为未来抗癌药物开发的合适先导化合物。本研究旨在阐明新合成的螺旋甾辛胺类似物同螺旋甾辛胺(KP7)的抗增殖/细胞毒性作用的机制。该评估是在宫颈癌细胞上进行的,这是一种最常见的癌症类型的体外模型,也是全球女性癌症死亡率的重要原因。用同螺旋甾辛胺(2.0 μM)处理 24、48 和 72 h 可显著抑制 HeLa 细胞的体外生长,并诱导 DNA 片段化、磷脂酰丝氨酸外翻、线粒体膜电位耗散、caspase-3 激活和 PARP 裂解可检测到的细胞凋亡。此外,用螺旋甾辛胺处理 HeLa 细胞可增加蛋白水平的 p27 和 Bcl-2 以及 Bcl-2 在 Ser70 残基上的磷酸化。这些结果支持了这里所代表的螺旋甾辛胺类似物在未来治疗开发中的潜力。